title: [Successful eradication of H. pylori in an elderly patient with gastric cancer after effective UFT-E therapy].
abstract: The patient was a 83-year-old female with 2' T2-type gastric cancer associated with positive H. pylori in the lesser curvature of the stomach. The patient was treated with oral UFT-E alone in a daily dose of 400 mg. The tumor exhibited an O' IIa + IIc-like appearance 4 weeks after the start of administration and became scarred 8 weeks later, revealing marked tumor reduction in a short period of time. At 8 weeks, biopsy showed marked polymorphonuclear cells infiltration of gastric mucosa with no evidence of malignancy. In an attempt to eradicate H. pylori, 30 mg of lansoprazole, 400 mg of clarithromycin, and 2.0 g of ecabet-Na (3.0 g of Gastrom) were administered for 2 weeks. H. pylori was found to have been successfully eradicated, and the inflammatory lesions were no longer visible histologically. UFT-E was highly effective in this patient, and the eradication of H. pylori may contribute to the prevention of cancer recurrence.
authors.affiliation: Dept. of Internal Medicine, Omura Municipal Hospital.
authors.forename: K
authors.initials: K
authors.lastname: Matsunaga
authors.forename: M
authors.initials: M
authors.lastname: Oofukuji
authors.forename: S
authors.initials: S
authors.lastname: Syukuwa
authors.forename: M
authors.initials: M
authors.lastname: Osabe
authors.forename: Y
authors.initials: Y
authors.lastname: Takeno
authors.forename: H
authors.initials: H
authors.lastname: Isomoto
authors.forename: Y
authors.initials: Y
authors.lastname: Mizuta
authors.forename: S
authors.initials: S
authors.lastname: Kohno
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D045784:Abietanes; D000230:Adenocarcinoma / Q000188:drug therapy* / Q000382:microbiology; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017291:Clarithromycin / Q000008:administration & dosage; D004224:Diterpenes / Q000008:administration & dosage; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000302:isolation & purification; D006801:Humans; D064747:Lansoprazole; D009853:Omeprazole / Q000008:administration & dosage / Q000031:analogs & derivatives; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000382:microbiology; D005641:Tegafur / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D045784:Abietanes; D000900:Anti-Bacterial Agents; D004224:Diterpenes; D064747:Lansoprazole; D005641:Tegafur; C061681:ecabet; D014498:Uracil; D017291:Clarithromycin; D009853:Omeprazole